Dupixent is available as a solution inside single-dose prefilled pens and syringes, given as a subcutaneous injection. Dupixent is a biologic and belongs to a drug class called interleukin-4 (IL-4 ...

AstraZeneca's first-in-class severe asthma therapy Tezspire has been approved in the EU in a new pen injector formulation ... is delivered as a pre-filled syringe (pictured above) that is dosed ...

CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent ... with the launch of a prefilled syringe in mid-2025 and label expansions for ...

Several YouTube videos shot by an 11-year-old girl in Jaipur, including one that showed her playing with a syringe, have highlighted the impact of social media on children and drawn strong remarks ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

The company’s Eylea product line, particularly the Eylea HD, has promising developments with a pre-filled syringe application ... the successful launch of Dupixent for chronic obstructive ...

Friendly germs armed with their own biological syringes and poisons could hold the key to overcoming the antimicrobial resistance crisis, according to a new study by biologists at the Universities ...

NovoPen ®, the first insulin pen injector, was introduced in 1985 ... as conventional insulin regimens employing syringes. The published evidence identified also showed that insulin ...

In this study, significantly more patients in the insulin pen group prepared and self-injected at least one dose of insulin compared with the vial and syringe group. Patients with newly diagnosed ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...